|Awarded On||February 21, 2018|
|Title||Clinical trials of C188-9, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with hepatocellular carcinoma (HCC)|
|Award Mechanism||Individual Investigator Research Awards for Clinical Translation|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||David J Tweardy|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
Hepatocellular carcinoma (HCC) is the world’s second leading cause of cancer-related death, in part, because patients often present with advanced disease when treatment is limited to sorafenib, which increases survival by only 3 months. Clearly, new treatments for advanced HCC are needed. Findings by our group and others indicate that a cancer-causing protein within tumor cells called STAT3 is worth targeting in HCC. To begin to test this possibility, our group, worked with a small pharmaceutical firm (StemMed, Ltd.) to identify a small molecule, C188-9, that enters the cell, binds directly to STAT3 with high affinity, and blocks STAT3’s ability to function. We examined the effect of C188-9 ...